References

1. Khoury, J.D., Solary, E., Abla, O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36, 1703–1719 (2022). https://doi.org/10.1038/s41375-022-01613-1
2. RH Zulkeflee et al., “Clinical and laboratory features of JAK2 V617F, CALR, and MPL mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN),” Int J Environ Res Public Health, 18, 14 (2021). PMID: 34300032.
3. National Comprehensive Cancer Network, “NCCN guidelines: myeloproliferative neoplasms” (2026). Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477.
4. X Liu et al., “A comparison of sequential polymerase chain reaction–based cascade testing vs next-generation sequencing in molecular profiling of myeloproliferative neoplasms: improving testing strategies in light of evolving molecular landscapes,” Lab Med, 56, 5 (2025). PMID: 40238187.